MammaPrint® is a test that helps determine the benefit of using chemotherapy in addition to hormone therapy for some estrogen receptor-positive (ER-positive), HER2-negative breast cancers.
Every cell in your body has genes that contain the blueprints (genetic code) for your body. Similarly, every cell in a breast tumor has genes. These genes contain the blueprints for the tumor.
Tumor profiling (using gene expression profiling tools) gives information about the genes in cancer cells. MammaPrint is a tumor profiling test.
MammaPrint tests a sample of the tumor (removed during a biopsy or surgery) for a group of 70 genes.
Along with other factors, the results of the MammaPrint test help predict the chance of metastasis (when cancer spreads to other organs).
If MammaPrint results show a person has a fairly high risk of metastasis, a more aggressive treatment plan that includes both hormone therapy and chemotherapy may be advised [36-37].
If MammaPrint results show a low risk of metastasis, the use of hormone therapy alone may be considered.
In this way, MammaPrint may help some people avoid chemotherapy and its side effects.
MammaPrint helps predict the chance of metastasis for some breast cancers at high clinical risk of recurrence (based on estrogen receptor status, HER2 status, tumor grade, lymph node status and tumor size).
MammaPrint can be used for high clinical risk breast cancers that are all of the following [36-37]:
Breast Cancer Prognosis
Research Fast Facts
HER2 and Breast Cancer
1-877 GO KOMEN(1-877-465-6636)